Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other financing activities (2024 - 2025)

ARS Pharmaceuticals' Other financing activities history spans 2 years, with the latest figure at -$2.7 million for Q3 2025.

  • For Q3 2025, Other financing activities fell 231.38% year-over-year to -$2.7 million; the TTM value through Sep 2025 reached -$42000.0, changed N/A, while the annual FY2020 figure was $2.6 million, N/A changed from the prior year.
  • Other financing activities for Q3 2025 was -$2.7 million at ARS Pharmaceuticals, down from $2.7 million in the prior quarter.
  • Across five years, Other financing activities topped out at $2.7 million in Q2 2025 and bottomed at -$2.7 million in Q3 2025.